نورميتن ٥٠ إسرائيل - العربية - Ministry of Health

نورميتن ٥٠

abic ltd. - atenolol 50 mg - tablets - atenolol - management of angina pectoris and hypertension, including hypertension of renal origin. late intervention after acute myocardial infarction

نورميتن ٢٥ إسرائيل - العربية - Ministry of Health

نورميتن ٢٥

abic ltd. - atenolol 25 mg - tablets - beta blocking agents, selective - management of angina pectoris and hypertension, including hypertension of renal origin. late intervention after acute myocardial infarction.

روزوڤاساتين تيڤع ١٠ ملغ إسرائيل - العربية - Ministry of Health

روزوڤاساتين تيڤع ١٠ ملغ

teva pharmaceutical indust.ltd - rosuvastatin as calcium 10 mg - tablets - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

ميرتازاپين تيڤع ۳٠ ملغ إسرائيل - العربية - Ministry of Health

ميرتازاپين تيڤع ۳٠ ملغ

teva pharmaceutical indust.ltd - mirtazapine 30 mg - tablets - mirtazapine - episode of major depression.

بيكالوتاميد تيڤع ٥٠ ملغ إسرائيل - العربية - Ministry of Health

بيكالوتاميد تيڤع ٥٠ ملغ

teva pharmaceutical indust.ltd - bicalutamide 50 mg - tablets - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.

بيكالوتاميد تيڤع ١٥٠ ملغ إسرائيل - العربية - Ministry of Health

بيكالوتاميد تيڤع ١٥٠ ملغ

teva pharmaceutical indust.ltd - bicalutamide 150 mg - tablets - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.